Skip to main content

01-10-2019 | Renal cell carcinoma | ESMO 2019 | Article

Researcher comment: JAVELIN Renal 101 – Combination approach for advanced RCC patients without upfront cytoreductive nephrectomy

Laurence Albiges discusses a JAVELIN Renal 101 subgroup analysis indicating that avelumab plus axitinib achieves tumor reduction in patients with metastatic renal cell carcinoma (2:30).

Receive weekly updates on the oncology news that matters

Read the transcript

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA.

Back to the WCLC 2019 conference hub

Related topics